Dosing is underway in a Phase 2a clinical trial evaluating Frequency Therapeutics’ (FREQ +1.5%) lead candidate FX-322 in patients with stable sensorineural hearing loss (SNHL) (the most common type).
The primary efficacy endpoints are three measures
of hearing ability at day 210 compared to placebo. The estimated
completion date is September 2020.
The company says FX-322
is a small molecule designed to treat the underlying cause of SNHL by
regenerating hair cells via the activation of progenitor cells in the
cochlea (spiral cavity in the inner ear).
https://seekingalpha.com/news/3505021-frequency-therapeutics-launches-mid-stage-study-hearing-loss-candidate-fxminus-322
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.